Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.19
-2.5%
$0.00
$0.87
$3.07
$33.76M0.15343,708 shs83,337 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$0.65
-0.9%
$0.68
$0.43
$1.71
$121.73M0.621.84 million shs1.05 million shs
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$1.23
+43.3%
$0.98
$0.71
$4.60
$113.52M-0.041.27 million shs4.44 million shs
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$5.06
+4.5%
$3.44
$1.97
$22.71
$151.45M1.2300,604 shs66,744 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
+0.42%-0.92%-7.47%+4.57%-43.87%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-0.89%-4.51%-4.62%-29.83%-62.62%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
+43.34%+46.69%+42.26%-1.60%-73.43%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
+4.55%+15.79%+52.41%+5.64%-78.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.1416 of 5 stars
3.53.00.04.22.32.50.6
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
4.2572 of 5 stars
3.24.00.04.22.61.71.3
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
3.4578 of 5 stars
4.44.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5026.05% Upside
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.00
Buy$4.50587.97% Upside
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.33
Hold$3.00143.90% Upside
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83568.64% Upside

Current Analyst Ratings Breakdown

Latest ANTX, SLN, NKTR, and RAPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.00
5/22/2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$6.00
5/12/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/11/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$1.00 ➝ $2.00
3/14/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$6.00
3/13/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/13/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$87.25M1.40N/AN/A$0.69 per share0.95
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
$1.53M106.35N/AN/A$4.27 per share0.29
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$27.70M5.47N/AN/A$0.71 per share7.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$276.06M-$0.64N/AN/AN/A-180.70%-173.28%-46.31%N/A
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%N/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/A

Latest ANTX, SLN, NKTR, and RAPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$0.18-$0.22-$0.04-$0.24$15.61 million$10.46 million
5/8/2025Q1 2025
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$0.31-$0.08+$0.23-$0.08N/AN/A
5/8/2025Q1 2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
3/12/2025Q4 2024
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$0.18$0.15+$0.33$0.03$36.65 million$29.18 million
3/6/2025Q4 2024
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
-$0.45-$1.14-$0.69-$1.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
4.24
4.24
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
N/A
9.90
9.90
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/A
9.31
9.31

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
99.09%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
5.25%
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
2.36%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
220186.10 million177.62 millionOptionable
RAPT Therapeutics, Inc. stock logo
RAPT
RAPT Therapeutics
80132.29 million32.65 millionOptionable
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
10029.93 millionN/ANot Optionable

Recent News About These Companies

Silence Therapeutics plc GAAP EPS of -C$0.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$0.65 -0.01 (-0.89%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.65 0.00 (-0.32%)
As of 05/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

RAPT Therapeutics stock logo

RAPT Therapeutics NASDAQ:RAPT

$1.23 +0.37 (+43.34%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.20 -0.03 (-2.44%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.06 +0.22 (+4.55%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$5.07 +0.01 (+0.28%)
As of 05/23/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.